Neurofilament light chain, a biomarker for polyneuropathy in systemic amyloidosis by Louwsma, Jelger et al.
 
 
 University of Groningen
Neurofilament light chain, a biomarker for polyneuropathy in systemic amyloidosis
Louwsma, Jelger; Brunger, Anne F.; Bijzet, Johan; Kroesen, Bart J.; Roeloffzen, Wilfried W.





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2020
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Louwsma, J., Brunger, A. F., Bijzet, J., Kroesen, B. J., Roeloffzen, W. W. H., Bischof, A., Kuhle, J., Drost,
G., Lange, F., Kuks, J. B. M., Gans, R. O. B., Hazenberg, B. P. C., & Nienhuis, H. L. A. (2020).
Neurofilament light chain, a biomarker for polyneuropathy in systemic amyloidosis. Amyloid, 1-6.
https://doi.org/10.1080/13506129.2020.1815696
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 26-12-2020
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=iamy20
Amyloid
The Journal of Protein Folding Disorders
ISSN: (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/iamy20
Neurofilament light chain, a biomarker for
polyneuropathy in systemic amyloidosis
Jelger Louwsma , Anne F. Brunger , Johan Bijzet , Bart J. Kroesen , Wilfried W.
H. Roeloffzen , Antje Bischof , Jens Kuhle , Gea Drost , Fiete Lange , Jan B. M.
Kuks , Reinold O. B. Gans , Bouke P. C. Hazenberg & Hans L. A. Nienhuis
To cite this article: Jelger Louwsma , Anne F. Brunger , Johan Bijzet , Bart J. Kroesen ,
Wilfried W. H. Roeloffzen , Antje Bischof , Jens Kuhle , Gea Drost , Fiete Lange , Jan B.
M. Kuks , Reinold O. B. Gans , Bouke P. C. Hazenberg & Hans L. A. Nienhuis (2020):
Neurofilament light chain, a biomarker for polyneuropathy in systemic amyloidosis, Amyloid, DOI:
10.1080/13506129.2020.1815696
To link to this article:  https://doi.org/10.1080/13506129.2020.1815696
© 2020 The Author(s). Published by Informa
UK Limited, trading as Taylor & Francis
Group.
Published online: 04 Sep 2020.
Submit your article to this journal 
Article views: 488
View related articles 
View Crossmark data
ARTICLE
Neurofilament light chain, a biomarker for polyneuropathy in systemic
amyloidosis
Jelger Louwsmaa,b , Anne F. Brungera,b, Johan Bijzetb,c , Bart J. Kroesenb,d, Wilfried W. H. Roeloffzenb,e,
Antje Bischoff, Jens Kuhlef, Gea Drostb,g, Fiete Langeb,g, Jan B. M. Kuksb,g, Reinold O. B. Gansa,b,
Bouke P. C. Hazenbergb,c and Hans L. A. Nienhuisa,b
aDepartment of Internal Medicine, University Medical Center Groningen, Groningen, The Netherlands; bAmyloidosis Center of Expertise,
University Medical Center Groningen, Groningen, The Netherlands; cDepartment of Rheumatology & Clinical Immunology, University
Medical Center Groningen, Groningen, The Netherlands; dDepartment of Laboratory medicine, University Medical Center Groningen,
Groningen, The Netherlands; eDepartment of Hematology, University Medical Center Groningen, Groningen, The Netherlands; fDepartment
of Neurology, University Hospital Basel, Basel, Switzerland; gDepartment of Neurology, University Medical Center Groningen, Groningen, The
Netherlands
ABSTRACT
Objective: To study serum neurofilament light chain (sNfL) in amyloid light chain (AL) amyloidosis
patients with and without polyneuropathy (PNP) and to corroborate previous observations that sNfL is
increased in hereditary transthyretin-related (ATTRv) amyloidosis patients with PNP.
Methods: sNfL levels were assessed retrospectively in patients with AL amyloidosis with and without
PNP (AL/PNPþ and AL/PNP–, respectively), patients with ATTRv amyloidosis and PNP (ATTRv/PNPþ),
asymptomatic transthyretin (TTR) gene mutation carriers (TTRv carriers) and healthy controls. Healthy
controls (HC) were age- and sex-matched to both AL/PNP– (HC/AL) and TTRv carriers (HC/TTRv). The
single-molecule array (Simoa) assay was used to assess sNfL levels.
Results: sNfL levels were increased both in 10 AL/PNPþpatients (p< .001) and in 10 AL/PNP– patients
(p< .005) compared to 10 HC/AL individuals. sNfL levels were higher in AL/PNPþpatients than in AL/
PNP– patients (p< .005). sNfL levels were also increased in 15 ATTRv/PNPþpatients, compared to
both 15 HC/TTRv (p< .0001) and 15 TTRv carriers (p< .0001). ATTRv/PNPþpatients with progressive
PNP (PND-score> I) had the highest sNfL levels compared to patients with early PNP (PND-score I)
(p¼ .05). sNfL levels did not differ between TTRv carriers and HC/TTRv individuals. In the group com-
prising all healthy controls and in the group of TTRv carriers, sNfL levels correlated with age.
Conclusion: sNfL levels are increased in patients with PNP in both AL and ATTRv amyloidosis and are
related to severity of PNP in ATTRv amyloidosis. sNfL is a promising biomarker to detect PNP, not only
in ATTRv but also in AL amyloidosis.
Abbreviations: AL: amyloid light chain; AL/PNPþ: amyloid light chain amyloidosis with polyneurop-
athy; AL/PNP-: amyloid light chain amyloidosis without polyneuropathy; ATTRv: hereditary transthyre-
tin-related amyloid; ATTRv/PNPþ: hereditary transthyretin-related amyloidosis with polyneuropathy;
CMAP: compound muscle action potentials; EMG: electromyography; FLC: immunoglobulin free light
chain; HC/AL: age- and sex-matched healthy controls for patients with amyloid light chain amyloidosis;
HC/Total: all healthy controls; HC/TTRv: age- and sex-matched healthy controls for asymptomatic TTR
mutation carriers; NCS: nerve conduction studies; NfL: neurofilament light chain; PND: polyneuropathy
disability; Simoa: single-molecule array; SNAP: sensory nerve action potential; sNfL: serum neurofila-
ment light chain; TTR: transthyretin; TTRv carrier: asymptomatic carrier of a pathogenic TTR mutation.
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Amyloid light chain (AL) amyloidosis and hereditary
transthyretin-related (ATTRv) amyloidosis are two of the
main types of systemic amyloidosis [1]. In both AL and
ATTRv amyloidosis the peripheral motor and sensory
nerves are frequently affected, leading to a progressive
axonal sensorimotor polyneuropathy (PNP) [2,3].
Detecting PNP at an early stage is important for
diagnosing new patients and is crucial for prognosis and
choice of treatment in patients.
This is particularly relevant because there are several
drugs available that delay or even halt disease progression of
ATTRv amyloidosis. Importantly, these treatments have
greater benefit when started early in the course of the dis-
ease [4–7]. In patients with AL amyloidosis, PNP is the pre-
senting manifestation in about 10% of patients [8,9].
However, if specifically looked for, PNP can be found in
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25–39% of patients [8,10,11]. The emergence or progression
of PNP during follow-up should raise suspicion of disease
progression. In this respect, detecting PNP is helpful in
diagnosing and monitoring patients.
In patients with proven systemic amyloidosis, PNP is a
clinical diagnosis for which EMG examination (often refer-
ring to nerve conduction studies and needle electromyog-
raphy) is commonly used to confirm axonal degeneration
[12,13]. However, this method is to some degree burden-
some for patients, does not detect small fibre neuropathy,
has limited sensitivity for axonal damage in early disease
stages and is only part of a composite method to evaluate
gradual progression of the PNP [14,15]. There is a clear
clinical need for an easily applicable serum biomarker for
both the early detection and follow-up of PNP in systemic
amyloidosis.
Neurofilament light chain (NfL), a major cytoskeletal
protein of neurons, is released into the blood and cerebro-
spinal fluid after axonal damage. Serum NfL (sNfL) has
been shown to be a promising biomarker for PNP in several
diseases affecting the peripheral nervous system [16,17].
However, the diagnostic value of sNfL as a biomarker for
PNP in systemic amyloidosis has not been studied in detail.
Two recent reports suggest that sNfL is increased in patients
with ATTRv amyloidosis and PNP [18,19].
The objective of this study is to investigate the relation-
ship between sNfL and PNP in patients with AL amyloidosis
and to corroborate previous observations that sNfL is
increased in patients with ATTRv amyloidosis and PNP.
Methods
Study participants
Patients with AL and ATTRv amyloidosis were diagnosed
according to current guidelines [20,21]. Patients who visited
the University Medical Center Groningen (UMCG) between
January 2010 and December 2018 were assessed for eligibil-
ity based on information available in their electronic patient
records in this retrospective study.
Two groups of patients with AL amyloidosis were
selected: one group with PNP (AL/PNPþ) (N¼ 10), and a
second group without PNP (AL/PNP–) (N¼ 10). PNP was
defined as symmetrical distal neuropathic symptoms or
signs of sensory loss. The absence of PNP was defined as no
neuropathic symptoms or signs of sensory loss. As periph-
eral neuropathy is primarily a clinical diagnosis in AL amyl-
oidosis [22], EMGs were not routinely performed and were,
therefore, not available for most of the patients. AL amyl-
oidosis patients were treatment naïve at the time of serum
sample collection. In patients with AL amyloidosis, the
severity of PNP was graded according to the National
Cancer Institute-Common Toxicity Criteria (NCI-CTC)
grading scale [22].
Patients with ATTRv amyloidosis were included if they
had PNP (ATTRv/PNPþ) (N¼ 15). PNP was defined as
symmetrical distal neuropathic symptoms, or signs of sen-
sory loss and had to be confirmed by EMG examination. In
patients with ATTRv amyloidosis, disease severity was
assessed using the Polyneuropathy Disability Score (PND)
[20]. Individuals with a pathogenic mutation in the TTR
gene, but without any sign or symptom of disease (neuro-
logical, cardiac, gastro-intestinal and ocular), normal EMG
results and the absence of amyloid in subcutaneous adipose
tissue and in other available tissues, were included as
asymptomatic carriers (TTRv carriers) (N¼ 15).
Healthy controls without any signs or symptoms of PNP
were age- and sex-matched for both the AL/PNP– group (HC/
AL) (N¼ 10) and the TTRv carriers (HC/TTRv) (N¼ 15).
All procedures were in compliance with the Declaration of
Helsinki. The study was approved by the institutional review
board of the UMCG Registration number: 201900860.
Blood sample collection and NfL measurement
Blood samples were drawn at the outpatient clinic of the
UMCG, centrifuged at 2700 rpm for 10min at room tem-
perature and stored within 1 h at –20 C. Samples were
coded and sent blinded for clinical details to the University
Hospital Basel for analysis of sNfL levels. Serum NfL was
measured using the ultrasensitive single-molecule array
assay (Simoa; NF-light Advantage Kit) using a HD-X plat-
form (Quanterix).
Statistical analysis
Data were analysed at the UMCG. sNfL levels were com-
pared using a two-sided Mann–Whitney U test. Correlations
between sNfL and age, creatinine, Troponin T and NT-
proBNP were determined using Spearman’s correlation co-
efficient. A p value  .05 was considered significant.
Statistical analysis was performed using SPSS version 23
(IBM Corp, Armonk, New York, USA). GraphPad Prism
7.02 (GraphPad Software, La Jolla, California, USA) was
used to generate graphs.
Results
Clinical and demographic characteristics
Characteristics of patients are shown in Table 1. There was
no age difference between AL patients with and without
PNP. AL patients with PNP had higher serum levels of NT-
proBNP and Troponin T compared to patients with-
out PNP.
TTRv carriers were younger than ATTRv patients with
PNP. Twelve of the ATTRv patients with PNP were treated
with tafamidis. ATTRv patients had higher serum levels of
NT-proBNP and Troponin T compared to TTRv carriers.
Genotype distribution of the ATTRv patients with PNP:
TTRV30M (p.Val50Met) (N¼ 5), TTRE89K (p.Glu109Lys)
(N¼ 3), TTRS23N (p.Ser43Asn) (N¼ 2), TTRG47E
(p.Gly67Glu) (N¼ 1), TTRA45G (p.Ala65Gly) (N¼ 1),
TTRY114C (p.Tyr134Cys) (N¼ 1), TTRV122del
(p.Val142Del) (N¼ 1) and TTRV71A (p.Val91Ala) (N¼ 1).
Genotype distribution of the TTRv carriers: TTRV30M
(p.Val50Met) (N¼ 9), TTRE89K (p.Glu109Lys) (N¼ 2),
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TTRY114C (p.Tyr134Cys) (N¼ 2), TTRV71A (p.Val91Ala)
(N¼ 1) and TTRV94A (p.Val114Ala) (N¼ 1).
sNfL levels in AL amyloidosis
In AL patients with PNP the median sNfL level was 6.6-fold
higher compared to AL patients without PNP and 11-fold
higher compared to matched healthy controls, whereas a
significant, yet smaller, increase was found in AL
patients without PNP compared to matched healthy controls
(Table 1 and Figure 1).
sNfL levels in ATTRv amyloidosis
In ATTRv patients with PNP the median sNfL level was
9.6-fold higher compared to TTRv carriers and 7.5-fold
higher compared to matched healthy controls, whereas sNfL
levels did not differ between the TTRv carriers and the
matched healthy controls group (Table 1 and Figure 1).
sNfL levels and PNP disease severity
sNfL levels were increased in patients with ATTRv amyloid-
osis and a PND score of I compared to asymptomatic car-
riers. sNfL levels were increased in ATTRv patients with a
PND score> I compared to those with a PND score of I
(Figure 2(A)). sNfL levels were increased in patients with
ATTRv amyloidosis and EMG findings indicating PNP,
compared to asymptomatic carriers with normal EMG find-
ings. sNfL levels were even higher in patients in whom no
response could be elicited in the sural nerve. The
classification of patients based on EMG findings largely cor-
responds to the classification based on PND score (Figure
2(B)). sNfL levels correlated with the sural nerve amplitude
in ATTRv patients with the amplitude set on 0 in patients
in whom no response could be elicited (r ¼ –0.5, p¼ .05).
However, sNfL levels did not correlate with the sural nerve
amplitude in TTRv carriers. sNfL levels did not correlate
with digit 5 ulnar nerve amplitude. sNfL levels correlated
with Troponin T levels in AL patients without PNP (r¼ 0.7,
p¼ .02), in AL patients with PNP (r¼ 0.8, p¼ .005) and in
ATTRv patients with PNP (r¼ 0.59, p¼ .02). sNfL levels did
not correlate with NT-proBNP levels or creatinine levels.
sNfL levels and age
sNfL levels in a group comprising all healthy controls (HC/
Total; median 9.9, IQR 7.9–15.0 pg/mL) correlated with age
(r¼ 0.57, p¼ .007; Figure 3). A correlation was also found
in TTRv carriers (r¼ 0.76, p¼ .001; Figure 3), but not in
patients with AL and ATTRv amyloidosis.
Discussion
This study demonstrates that sNfL levels are increased in
patients with PNP due to AL amyloidosis, and confirms pre-
vious studies showing that sNfL levels are increased and
correlate with severity of PNP in patients with PNP due to
ATTRv amyloidosis [18,19]. This study indicates that sNfL
is a useful biomarker for PNP diagnosis and severity, not
only in ATTRv, but also in AL amyloidosis.
The increased sNfL levels found in amyloidosis patients
with PNP are probably the result of axonal degeneration,
Table 1. Characteristics of the patients with AL and ATTRv amyloidosis, TTRv carriers and healthy controls.
AL/PNP– (N¼ 10) AL/PNPþ (N¼ 10) HC/AL (N¼ 10)
Age, years 65 ± 3 68 ± 2 66 ± 3
Gender (male/female) 5/5 6/4 5/5
sNfL, pg/mL 22.7 (18.6–37.6) 149 (64.2–329) 13.6 (9.8–17.3)†,§
NT-proBNP, ng/L 518 (334–652) 4462 (910–10,964) NA
Troponin T, ng/L 23 (11–38) 113 (44–131) NA
Creatinine, mmol/L 84 (77–118) 82 (69–169) NA
FLC difference, mg/L 169 (61–356) 132 (62–570) NA
Grade polyneuropathy, N
1 0 9 NA
2 0 1 NA
TTRv carriers (N¼ 15) ATTRv/PNPþ (N¼ 15) HC/TTRv (N¼ 15)
Age, years 43 ± 3 59 ± 4 46 ± 3
Gender (male/female) 7/8 10/5 6/9
sNfL, pg/mL 6.9 (4.8–11.8) 66.4 (18.2–138) 8.8 (6.5–11.4)§§
NT-proBNP, ng/L 56 (22–85) 586 (79–1409) NA
Troponin T, ng/L 4 (1–5) 30 (10–59) NA
Creatinine, mmol/L 76 (64–84) 73 (66–91) NA
PND score, N
I 0 8 NA
>I 0 7 NA
Unless stated otherwise, data are expressed as mean ± standard deviation when normally distributed and median (interquar-
tile range) when non-normally distributed.
NA: not assessed.
AL amyloidosis without PNP (AL/PNP–) and with PNP (AL/PNPþ); Healthy controls matched for age and sex with AL (HC/AL)
and with TTRv carriers (HC/TTRv); ATTRv amyloidosis with PNP (ATTRv/PNPþ) and asymptomatic carriers of pathogenic TTR
gene mutations (TTRv carriers).
AL/PNPþ versus AL/PNP– and ATTR/PNPþ versus TTRv carriers: <.05, <.01, <.005, <.0001.
AL/PNP– versus HC/AL and ATTRv/PNP- versus HC/TTRv: †<.005.
AL/PNPþ versus HC/AL and ATTR/PNPþ versus HC/TTRv: §<.001, §§<.0001.
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which is the final common pathway leading to release of
NfL in many inherited and acquired neuropathies [16,17].
Our current understanding of the underlying pathophysio-
logical mechanism leading to axonal degeneration in amyl-
oidosis is accumulation of amyloid fibrils within the
endoneurium and around nerve blood vessels as well as dir-
ect toxicity to the nerve of prefibrillar oligomers [23,24].
Interestingly, in AL amyloidosis sNfL levels were not
only increased in patients with PNP, but also in those with-
out PNP, compared to healthy controls. These results are
suggestive of subclinical axonal damage in patients with AL
amyloidosis without clinically overt PNP, which could be
caused by amyloid deposits or by direct neurotoxicity of
free light chains (FLCs) [2]. sNfL might be a sensitive
marker for early axonal damage in a presymptomatic stage
of AL amyloidosis. This might be of particular importance
for diagnosis, making treatment decisions (stratification of
patients at risk of developing symptomatic PNP) and moni-
toring of patients.
Levels of sNfL in TTRv carriers were comparable to sNfL
levels in healthy controls, suggesting that neuropathy in this
group of carriers is indeed absent. It should be noted, how-
ever, that subclinical neuropathy can already be present in
the TTRv carriers despite the use of strict selection criteria
(no signs or symptoms at all, normal EMG and a biopsy
without amyloid).
Compared to the TTRv carriers, levels of sNfL were
increased in early symptomatic patients (PND I) and more
Figure 1. Serum neurofilament light chain (sNfL) concentration in patients with AL amyloidosis without (AL/PNP–) and with polyneuropathy (AL/PNPþ), asymp-
tomatic TTRv-gene mutation carriers (TTRv carriers), ATTRv amyloidosis patients with polyneuropathy (ATTRv/PNPþ) and age- and sex-matched healthy controls
(HC/AL & HC/TTRv). Data are presented as median with interquartile range.
Figure 2. (A) Serum neurofilament light chain (sNfL) concentration in asymptomatic TTRv-gene mutation carriers (TTRv carrier) and ATTRv amyloidosis patients
with polyneuropathy (ATTRv/PNPþ). ATTRv/PNPþ patients were divided into two subgroups, those with solely sensory disturbances (polyneuropathy disability
(PND) score I) and those with impaired walking capability (PND score> I). Data are presented as median with interquartile range. (B) Serum neurofilament light
chain (sNfL) concentration in asymptomatic TTRv-gene mutation carriers (TTRv carrier) and ATTRv amyloidosis patients with polyneuropathy (ATTRv/PNPþ). ATTRv/
PNPþ patients were divided into two subgroups based on the sural sensory nerve action potential (SNAP), those with a decreased SNAP and those with an
undetectable SNAP. In all TTRv carriers SNAP was normal. Data are presented as median with interquartile range. Unfilled circles indicate patients with a
PND score> I.
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greatly increased in patients with progressive PNP
(PND> I). Likewise, the highest sNfL levels were found in
patients with the most pronounced EMG abnormalities.
These findings indicate that sNfL is a sensitive biomarker
for the detection of PNP in an early disease stage, and cor-
relates with severity of PNP. The results of our cohort of
patients with diverse TTR genotypes are in line with a
recent study of two independent cohorts of ATTR-V30Met
patients [18] and a recent study involving diverse TTR gen-
otypes [19].
Serum levels of NT-proBNP and Troponin T were
increased in patients with PNP compared to patients with-
out PNP and TTRv carriers. sNfL levels correlated with
Troponin T in all patient groups, but not with NT-proBNP.
Troponin T is a marker for cardiac involvement and reflects
disease severity in systemic amyloidosis. As neurofilament
light chain is a neuron specific protein [25] we think it is
unlikely that cardiac involvement itself has biased the
results. However, cardiac neuronal damage might explain
the correlation between sNfL and Troponin T. Further stud-
ies are warranted to confirm this finding.
The positive relationship between NfL levels and age
observed in individuals without PNP (healthy controls and
TTRv carriers) has previously been reported [17,18]. We did
not find an age-dependent increase in sNfL levels in patients
with PNP. In these patients with PNP the severity of dis-
ease-induced axonal degeneration has a much greater effect
on sNfL levels (ranging between 10 and 1000 pg/mL) than
age (ranging between 10 and 30 pg/mL) and thus masking a
moderate underlying age-dependent increase.
Limitations
This study was designed to explore the applicability of
serum NfL as a biomarker for PNP in systemic amyloidosis.
For this purpose, a relatively small number of patients, with
and without PNP, were studied cross-sectionally. There are
some limitations to this study. First, all but one of the AL/
PNPþ patients had grade 1 PNP. Therefore, it was not pos-
sible to study the relationship between disease severity and
sNfL in patients with AL amyloidosis. Unfortunately, neur-
opathy impairment scores (NIS) were not available for most
of the patients with AL and ATTRv amyloidosis because of
the retrospective nature of our study. Using NIS scores
should be considered for future prospective studies as it is a
more sensitive way of quantifying neurological impairment
[26]. Second, the diagnosis of PNP in patients with AL amyl-
oidosis was based on clinical symptoms only and no objective
test was used to diagnose PNP or assess disease severity.
Third, the cross-sectional design of our study, leaves us
unable to investigate whether NfL is a useful biomarker to
detect neuronal damage in a presymptomatic stage. Fourth,
which is both a strength and a weakness and inevitable given
the rarity of ATTRv, the genotype distribution was quite het-
erogeneous and the degree of PNP varies among mutations.
This limits the generalizability of the findings.
Conclusion
NfL is a promising biomarker for the detection of PNP, not
only in ATTRv but also in AL amyloidosis. Serum NfL is
able to detect PNP in an early symptomatic disease stage
and correlates with severity of PNP. Longitudinal studies are
necessary to evaluate whether NfL is a sensitive marker for
the detection of both PNP and small fibre neuropathy early
in an asymptomatic stage in AL and ATTRv amyloidosis.
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Figure 3. Correlation between the serum neurofilament light chain (sNfL) concentration and age at blood sample collection in a group comprising all healthy con-
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